BIOGEN INC.
Ownership & governance
Executives 5Directors 10Avg age 63Avg tenure 5.1y
CV
Christopher Viehbacher
Chief Executive Officer
Age 66Since 2022-11-13Profile →
+14
Executives5
CV
Christopher Viehbacher→
Chief Executive Officer
Age 66Since 2022-11-13
RK
Robin Kramer→
Director of Finance/CFO
Age 60Since 2025-02-28
GH
Guy Hadari
Chief Tech/Sci/R&D Officer
—Since 2020-12-31
DQ
Daniel Quirk
Chief Tech/Sci/R&D Officer
—Since 2024-10-27
JG
Jane Grogan
Chief Tech/Sci/R&D Officer
Age 59Since 2023-10-01
Board of directors10
ER
Eric Rowinsky→
Director/Board Member
Age 69Since 2010-03-22
SS
Stephen Sherwin→
Director/Board Member
Age 77Since 2009-12-31
WH
William Hawkins→
Director/Board Member
Age 72Since 2019-06-18
JM
Jesus Mantas→
Director/Board Member
Age 57Since 2019-06-18
MF
Maria Freire→
Chairman
Age 71Since 2026-06-08
CV
Christopher Viehbacher→
Director/Board Member
Age 66Since 2022-11-13
SL
Susan Langer→
Director/Board Member
Age 35Since 2023-06-25
MP
Monish Patolawala→
Director/Board Member
Age 56Since 2023-12-31
Shareholders4
| Name | Stake | Shares |
|---|---|---|
| Fidelity Management & Research Co. LLC | 11.28 % | 16,652,975 |
| PRIMECAP Management Co. | 9.996 % | 14,757,607 |
| Fidelity Management & Research Co. LLC | 8.674 % | 12,805,741 |
| BlackRock Advisors LLC | 7.778 % | 11,483,566 |
Catalog · 2026-07-09
Proxy officers28
| Name | Role | Since | Shares |
|---|---|---|---|
| Maria Freire | Chairman | 2026-06-08 | - |
| Caroline D. Dorsa | Director or executive officer | 2010-01-01 | 31,002 |
| Christopher A. Viehbacher | Director or executive officer | 2022-01-01 | 110,587 |
| Christopher Viehbacher | Director/Board Member | 2022-11-13 | - |
| Eric K. Rowinsky | Director or executive officer | 2010-01-01 | 24,339 |
| Eric Rowinsky | Director/Board Member | 2010-03-22 | - |
| Jesus B. Mantas | Director or executive officer | 2019-01-01 | 9,758 |
| Jesus Mantas | Director/Board Member | 2019-06-18 | - |
Proxy · as of 2026-07-09
Group companies
| Name | Category |
|---|---|
| Biogen MA, Inc. | Biotechnology |
| Biogen MA, Inc. | Biotechnology |
| Biogen Belgium NV/SA | Biotechnology |
| Biogen Belgium NV/SA | Biotechnology |
| Biogen International GmbH | Pharmaceuticals: Major |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 238.05Range 175–300Analysts 31
175Mean 238.05300
- Strong buy 3
- Buy 19
- Hold 12
- Sell 1
Broker actions40 of 641
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | 256 | 2026-10-08 |
| HSBC | Maintained | Reduce | 175 | 2026-09-10 |
| Piper Sandler | Reiterated | Overweight | 245 | 2026-09-03 |
| RBC Capital | Maintained | Outperform | 260 | 2026-08-25 |
| Wolfe Research | Upgrade | Outperform | 300 | 2026-08-13 |
| Mizuho | Maintained | Outperform | 241 | 2026-08-04 |
| Citigroup | Maintained | Neutral | 215 | 2026-08-03 |
| UBS | Maintained | Buy | 240 | 2026-07-30 |
| HC Wainwright & Co. | Maintained | Buy | 251 | 2026-07-30 |
| Morgan Stanley | Maintained | Equal-Weight | 231 | 2026-07-30 |
| RBC Capital | Maintained | Outperform | 240 | 2026-07-30 |
| Canaccord Genuity | Maintained | Buy | 248 | 2026-07-30 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.